A global pharmaceutical company defended and restructured the pricing framework for a major therapeutic at renewal, aligning 20+ stakeholders across functions and geographies on a strategy covering up to $1 billion USD in annual revenue.
A global pharmaceutical company faced a pricing renewal for a high-profile therapeutic. The original pricing had been set during a period of acute urgency, when demand was immediate and the payer had limited leverage. Now, at renewal, the dynamic had reversed. The payer's position was that the public health need had diminished and pricing should reflect that. The client's own data told a different story: utilization remained high, the condition had shifted from acute episodes to an endemic pattern, and the therapeutic's role in the health system was, if anything, more entrenched than at launch.
The complexity went well beyond a standard pricing discussion. Internally, alignment was needed across medical affairs, market access, supply chain, multiple business unit heads, and a communications function whose work needed to run alongside negotiation strategy rather than follow it. The approval chain stretched from local leadership through regional commercial authority to global pricing and executive sign-off. Externally, counterparties included the national pharmaceutical benefits authority, the health minister, regional ministers, and senior clinical opinion leaders. The payer side alone involved procurement, clinical advisory, and political decision-makers with different priorities and different definitions of value.
The engagement opened with an intensive planning session bringing together the full country-level leadership team and global stakeholders. From there, the work moved into sustained preparation over several months, with regular sessions through execution.
The defining feature was a coordinated multi-channel approach. Negotiation strategy and communications were developed in parallel, not sequentially. Engagement with political stakeholders (ministers, clinical leaders, senior health officials) and commercial negotiation (pricing structure, stock commitments, distribution terms) ran as linked workstreams, each informed by and feeding into the other.
The economic argument was central: quantifiable impact on workforce productivity, reduced burden on hospitals and high-risk care settings, and a clear return-on-investment case for the payer. A laddered pricing structure was built, tying volume thresholds to rebate tiers so the payer's per-unit cost reduced as uptake scaled. Distribution terms addressed who would hold stock, fund inventory, and guarantee turnaround times.
Internal alignment was managed through the full approval chain: local leadership, regional authority, global pricing, and executive-level sign-off on both the strategy and the negotiation parameters.
A comprehensive pricing and access strategy was delivered with sign-off secured across all four levels of internal authority: local, regional, global pricing, and executive committee. More than 20 senior stakeholders across functions and geographies were aligned on a unified position. The pricing framework covered a therapeutic generating between $500 million and $1 billion USD in annual revenue. The coordinated approach, integrating communications, political engagement, and commercial strategy, became the operating model for the negotiation, equipping the team with a defensible position, prepared counters, and a political engagement plan that extended well beyond the pricing table.
Most engagements started exactly like this one.